Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 182,891 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 182,891 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $15.99, for a total transaction of $2,924,427.09. Following the transaction, the chief executive officer directly owned 2,276,354 shares in the company, valued at approximately $36,398,900.46. The trade was a 7.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Adaptive Biotechnologies Trading Down 0.2%

ADPT stock opened at $16.08 on Wednesday. The firm’s 50-day moving average is $16.85 and its two-hundred day moving average is $15.79. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -40.20 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same period last year, the firm posted ($0.23) earnings per share. The business’s revenue was up 51.0% on a year-over-year basis. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of ADPT. Westfield Capital Management Co. LP purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at $65,942,000. Price T Rowe Associates Inc. MD increased its stake in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the period. Invesco Ltd. lifted its stake in Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares in the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADPT has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Finally, Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.